TNFRSF4 and acute myeloid leukemia: Additionally, we used the Vizome data analysis tool [28], which contains data from the BEAT AML cohort, and examined the level of TNFRSF4 expression of relapsed (N = 22) was significantly higher than de novo non-M3 AML (N = 214) samples (p = 0.0099, Additional file 2: Figure S1H).